Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

Novo Nordisk · Phase 2 · Completed · Enrollment 564

NCT00422058

EudraCT 2006-004481-13

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Lira placebo/Lira 2.4 mg/Lira 3.0 mgn/rn/rn/rn/r
Lira 1.2 mg/Lira 3.0 mgn/rn/rn/rn/r
Lira 1.8 mg/Lira 3.0 mgn/rn/rn/rn/r
Lira 2.4 mg/Lira 3.0 mgn/rn/rn/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Orlistatn/rn/rn/rn/r

Not shown

  • Lira placebo/Lira 2.4 mg/Lira 3.0 mg: endpoint not reported
  • Lira 1.2 mg/Lira 3.0 mg: endpoint not reported
  • Lira 1.8 mg/Lira 3.0 mg: endpoint not reported
  • Lira 2.4 mg/Lira 3.0 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported
  • Orlistat: endpoint not reported